In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.

After a years-long revenue drought, there's a light at the end of the tunnel.

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

One of these suggested stocks features a dividend yield topping 10%.

Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently after the company announced its financial guidance for 2026, which fell short ...

Shares of Pfizer Inc. PFE shed 2.42% to $25.86 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.02% to ...

Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to ...

Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic ...